Publications by authors named "Ellen Ingalla"

Claim this Profile
P
Physiologically-based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans.
Anjani Ganti, Sijia Yu, Danielle Sharpnack, Ellen Ingalla, Tom De Bruyn

Biopharm Drug Dispos· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Elisabeth A Lasater, Dhara N Amin, Rajat Bannerji, Raghuveer Singh Mali, Kathy Barrett, Ellen Rei Ingalla

Am J Hematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
Jackson Liang, Ellen Rei Ingalla, Xiaosai Yao, Bu-Er Wang, Lisa Tai

Sci Transl Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.
Jun Liang, Jason R Zbieg, Robert A Blake, Jae H Chang, Stephen Daly, Ellen Rei Ingalla

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.
Jun Liang, Robert Blake, Jae Chang, Lori S Friedman, Simon Goodacre, Ellen Rei Ingalla

ACS Med Chem Lett· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.
Jane Guan, Wei Zhou, Marc Hafner, Robert A Blake, Cecile Chalouni, Ellen Ingalla

Cell· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Andrew D Zelenetz, Gilles Salles, Kylie D Mason, Carla Casulo, Steven Le Gouill, Ellen Ingalla

Blood· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha.
Birong Zhang, James R Kiefer, Robert A Blake, Jae H Chang, Steven Hartman, Ellen Rei Ingalla

Bioorg Med Chem Lett· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.
James D Joseph, Beatrice Darimont, Wei Zhou, Alfonso Arrazate, Amy Young, Ellen Ingalla

Elife· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conjugation of Indoles to Antibodies through a Novel Self-Immolating Linker.
Peter S Dragovich, Robert A Blake, Chunjiao Chen, Jinhua Chen, Josefa Chuh, Ellen Rei Ingalla

Chemistry· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.
James D Joseph, Beatrice Darimont, Wei Zhou, Alfonso Arrazate, Amy Young, Ellen Ingalla

Elife· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Elizabeth A Punnoose, Joel D Leverson, Franklin Peale, Erwin R Boghaert, Lisa D Belmont, Ellen Ingalla

Mol Cancer Ther· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.
Xiangnan Du, Benjamin C Lin, Qian-Rena Wang, Hao Li, Ellen Ingalla

Clin Cancer Res· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.
Ellen Q Ingalla, Jamie K Miller, Jessica H Wald, Heather C Workman, Rouminder P Kaur

J Biol Chem· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells.
Heather C Workman, Jamie K Miller, Ellen Q Ingalla, Rouminder P Kaur, Diane I Yamamoto

Breast Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.
Jamie K Miller, David L Shattuck, Ellen Q Ingalla, Lily Yen, Alexander D Borowsky

Cancer Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Lily Yen, Zhongwei Cao, Xiuli Wu, Ellen R Q Ingalla, Colin Baron

Cancer Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.
Melanie B Laederich, Melanie Funes-Duran, Lily Yen, Ellen Ingalla, Xiuli Wu

J Biol Chem· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis